drugset / Trial / NCT02987504
Study of Samalizumab in Patients With Advanced Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, dose-escalation, Phase 1 study of intravenous (IV) samalizumab to determine its maximum tolerated dose (MTD), overall safety/tolerability, pharmacokinetic and pharmacodynamic parameters, and efficacy in participants with advanced cancer. The study was terminated for administrative reasons and not due to any safety concerns.
Timeline
- Start
- 2016-11-17
- Primary completion
- 2017-09-12
- Completion
- 2017-09-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Samalizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Samalizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Samalizumab | Monoclonal antibody | 20 mg/kg | Intravenous |